Alumis Q2 FY26 net loss widens to $142.22 million; revenue falls 37.65% to $1.66 million - ALMS News | RalliesAlumis Q2 FY26 net loss widens to $142.22 million; revenue falls 37.65% to $1.66 million
A
ALMS• Q2 FY26 results
- Alumis posted a net loss of $142.2 million for Q2 2026, swinging from net income of $59.3 million a year earlier.
- Revenue fell 37.65% to $1.66 million, reflecting lower collaboration revenue tied to the Kaken licensing agreement.
Expenses and impairment
- Research and development expense declined 21.53% to $85.34 million, while general and administrative costs dropped 32.2% to $23.36 million.
- Operating expenses included a $41.82 million impairment tied to the lonigutamab program, following a decision to pursue strategic alternatives.
Cash position and outlook
- Cash, cash equivalents and marketable securities totaled $502.3 million.
- The company forecast runway into Q4 2027 and said a psoriasis NDA is planned for Q4 2026.
EMAT
•
